EFung Capital
VC Fund
Shenzhen, China
EFung Capital is a VC fund in Shenzhen focused on Health Care and Biotechnology. Shenzhen EFUNG Investment Management Enterprise L. P. is one of China's earliest institutions investing in professional biomedical industries. Their strong research team and great investment returns made us won 'The Most Pioneering VC Institution” 'The Most Dynamic Pharmaceutical VC Institution in China' and 'The Top Ten VCInstitutions in Shenzhen'. With this influence, EFUNG has drawn a lot of attention from the medical and life science industry. And it is interviewed by Nature, which is the most authoritative science magazine in the world. Over a decade of years, they have been focusing on the medical and health industry, especially the VC and PE investment business of novel drugs and high-end medical devices. The mission of EFUNG is to drive the industrialization of medical researches by capital and to gain rich returns to investors. EFUNG has deeply screened and invested in more than 20 domestic and international premium enterprises, such as Chipscreen Biosciences, Frontier Biotechnologies, Ascentage Pharma, Lifotronic, Aridis Pharmaceuticals, and Centrexion.
- Total investments:
- 82
- Last investment:
- Lead investor:
- 35%
Last updated:
For AI agents: llms.txt
Industries EFung Capital invests in
Stages EFung Capital invests in
Countries EFung Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Round size
- Series A
- $1.4M–$36M
- Series B
- $14M–$100M
- Series C
- $14M–$74M
Investment Focus
Industry
- Health Care 37 (45%)
- Biotechnology 33 (40%)
- Medical 21 (26%)
- Pharmaceutical 19 (23%)
- Medical Device 11 (13%)
Stage
- Series B 15 (18%)
- Series A 14 (17%)
- Series C 13 (16%)
- Funding Round 10 (12%)
- Seed 7 (9%)
Country
- China 52 (63%)
- United States 6 (7%)
- India 1 (1%)
- Japan 1 (1%)
- Canada 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Jinqiao Zhu
Founder
|
Founder | Total investments: 2 | Find email | |
|
Luo Fayong
Managing Director
|
Managing Director | Total investments: 1 | Find email | |
|
Pai Zhu
Managing Partner
|
Managing Partner | Total investments: 6 | Find email | |
|
Yu Wang
Chief Scientist
|
Chief Scientist | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
|
Heluo New Image is a cell treatment platform developer that focuses on iPSC directed differentiation, gene editing, large-scale cell product production, and cell therapy technology development. | $22.2M / Seed / Aug 07, 2026 | |
|
|
Xgene Pharmaceutical is a pharmaceutical company. | $36.9M / Series D / Jul 28, 2026 | |
|
|
Yuanma Intelligent Pharmaceuticals is a biopharmaceutical business that focuses on circular mRNA (cmRNA) treatments, namely in vivo cmRNA CAR-T cell therapy. | Seed / Jul 22, 2026 | |
|
|
Pinsun Bio is a technology innovation-driven company that focuses on core consumables and one-stop solutions for biopharmaceutical processes. | $14.8M / Series A / Jul 20, 2026 | |
|
|
Q1 2022 c-suite not found. | $14.8M / Jun 18, 2026 | |
|
|
Carbonology is a carbon capture company that produces fuels, chemicals, and polyesters. | Series A / Jun 12, 2026 | |
|
Carbon Life
|
Carbon Life is a carbon sequestration technology developer. It is mainly engaged in carbon emission reduction, carbon conversion, carbon capture, carbon sequestration technology research and development. | Series A / Jun 12, 2026 | |
|
|
Carbonology is a carbon capture company that produces fuels, chemicals, and polyesters. | Seed / Jun 12, 2026 | |
|
|
Barty Medical develops, manufactures, and markets coronary drug balloons, peripheral drug balloons, coronary PTCA balloons, peripheral PTA balloons, peripheral drug stents, supporting catheter sheaths, vascular interventional devices, and implanted devices. | $29.5M / Series D / Jun 10, 2026 | |
|
|
Vivolight is a medical research and development company. | Series E / Jun 01, 2026 | |
| See all 82 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does EFung Capital invest in?
EFung Capital invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series A stage. Most of the 82 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is EFung Capital's check size?
EFung Capital typically joins rounds of $1.4M–$36M at Series A, $14M–$100M at Series B and $14M–$74M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds EFung Capital participates in.
How do I contact EFung Capital?
Public channels for EFung Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at EFung Capital?
The team at EFung Capital includes Jinqiao Zhu (Founder), Luo Fayong (Managing Director) and Pai Zhu (Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!